Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

F Lo Coco, G Avvisati, M Vignetti, C Thiede, Sm Orlando, S Iacobelli, F Ferrara, P Fazi, L Cicconi, E Di Bona, G Specchia, Simona Sica, M Divona, A Levis, W Fiedler, E Cerqui, M Breccia, G Fioritoni, Hr Salih, M CazzolaL Melillo, Am Carella, Ch Brandts, E Morra, M Von Lilienfeld Toal, B Hertenstein, M Wattad, M Lübbert, M Hänel, N Schmitz, H Link, Mg Kropp, A Rambaldi, G La Nasa, M Luppi, F Ciceri, O Finizio, A Venditti, F Fabbiano, K Döhner, M Sauer, A Ganser, S Amadori, F Mandelli, H Döhner, G Ehninger, Rf Schlenk, U. Platzbecker

Risultato della ricerca: Contributo in rivistaArticolo

819 Citazioni (Scopus)

Abstract

All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity.
Lingua originaleInglese
pagine (da-a)111-121
Numero di pagine11
RivistaNew England Journal of Medicine
Volume369
Numero di pubblicazione2
DOI
Stato di pubblicazionePubblicato - 2013

All Science Journal Classification (ASJC) codes

  • Medicina Generale

Keywords

  • Acute
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Arsenicals
  • Consolidation Chemotherapy
  • Disease-Free Survival
  • Female
  • Humans
  • Induction Chemotherapy
  • Leukemia
  • Maintenance Chemotherapy
  • Male
  • Middle Aged
  • Neutropenia
  • Oxides
  • Promyelocytic
  • Thrombocytopenia
  • Tretinoin
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Retinoic acid and arsenic trioxide for acute promyelocytic leukemia'. Insieme formano una fingerprint unica.

Cita questo